September 24, 2012

Tonix Pharmaceuticals to Present at 2012 AEGIS Healthcare Conference

NEW YORK, NY -- (MARKETWIRE) -- 09/24/12 -- Tonix Pharmaceuticals Holding Corp. (OTCQB: TNXP) ("TONIX" or the "Company"), a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia ("FM") and post-traumatic stress disorder, today announced that Seth Lederman, M.D., Chief Executive Officer of TONIX, will present a corporate update at the 2012 Aegis Healthcare Conference taking place from September 27-29, 2012 at The Wynn in Las Vegas, Nevada. Dr. Lederman's presentation will take place on Friday, September 28th at 11:45 a.m. Pacific time.

The Company's presentation is available on its website atwww.tonixpharma.com.

About TONIX

TONIX is developing innovative prescription medications for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX's core technology improves the quality of sleep in patients with chronic pain syndromes, which is believed to translate into reductions in daytime pain. The Company's lead product candidate, TNX-102 Sublingual ("TNX-102 SL"), is a novel under-the-tongue tablet formulation of cyclobenzaprine ("CBP"), the active ingredient in two U.S. FDA-approved muscle relaxants, and is expected to enter a Phase 3 program in FM in early 2013. In a randomized, double-blind, placebo-controlled, eight-week Phase 2 trial, TONIX demonstrated that low-dose CBP given at bedtime resulted in a significant decrease in next-day pain and other core FM symptoms, as well as in a significant improvement in sleep quality. Legacy CBP products are widely used by FM patients, but are neither designed nor approved for this indication. TONIX developed TNX-102 SL to address the efficacy and tolerability limitations of current CBP products, and to optimize CBP for the treatment of chronic pain syndromes.

To learn more about the Company, please visitwww.tonixpharma.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on TONIX's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement;

limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. TONIX does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 30, 2012 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

Contacts:

Tonix Pharmaceuticals Holding Corp.
Benjamin Selzer
Chief Operating Officer
(212) 980-9155 x106
Email Contact

LHA
Anne Marie Fields
(212) 838-3777
Email Contact
or
Bruce Voss
(310) 691-7100
Email Contact